(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 30, 2024 (GLOBE NEWSWIRE) -- The "Contraceptive Drugs - market Insights, Competitive Landscape, and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
The global contraceptive drugs market is experiencing significant growth, driven by increased incidence of unintended pregnancies, heightened awareness of family planning, and the introduction of new products. The market, valued at USD 9.31 billion in 2023, is anticipated to grow at a compound annual growth rate (CAGR) of 4.30% from 2024 to 2030.
Recent data from international organizations highlights the pressing need for improved access to contraceptive drugs to address public health challenges associated with unintended pregnancies. Increased awareness and education about reproductive health have bolstered the demand for effective contraceptive methods. Governmental efforts and regulatory approvals are enabling better access to contraceptive drugs, further contributing to the market growth.
Segment Analysis and Leading Market Share
Oral contraceptive pills, injectables, and topical contraceptives constitute major segments within the market. Among them, oral contraceptives remain the dominant category, favored for their efficacy, convenience, and evolving formulations catering to various user preferences. North America holds the lion's share in the market, with growth attributed to rising awareness, government initiatives, and product accessibility. Efforts aligning with the United Nations Sustainable Development Goals are fostering market growth through increased demand and utilization.
Key Market Players
The market is characterized by a competitive landscape with key players, including major pharmaceutical companies, contributing to the market through innovation, strategic partnerships, and product approvals. These companies are instrumental in driving the market forward with the introduction of new products and initiatives that align with public health goals and address the needs of different consumer groups.
Recent Developmental Activities
The market has witnessed significant developments, such as the initiation of clinical trials for new potential drug formulations and the approval of innovative contraceptive drug options. These advancements reflect an ongoing commitment to addressing reproductive health needs and enhancing user safety and satisfaction.
Conclusion
With the anticipated market growth, increased product availability, and continued focus on female reproductive health, the contraceptive drugs market stands poised for continued expansion through 2030. The industry remains vital for supporting planned parenthood goals and improving health outcomes globally, presenting opportunities for market players and end-users alike.
Companies Featured
Pfizer Inc. Abbvie Inc. BAYER AG Gedeon Richter Plc. Mayne Pharma Merck & Co., Inc. Teva Pharmaceuticals Novartis AG Johnson & Johnson Sanofi Cipla Ltd. Zydus Cadila Torrent Pharmaceuticals Ltd. Mankind Pharma Dr. Reddy's Laboratories Glenmark Pharmaceuticals Aurobindo Pharma Limited Amneal Pharmaceuticals LLC. Maxwellia Ltd. Theramex
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT:
CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN30102024004107003653ID1108834302
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.